Camlin Fine Sciences Limited shareholders approved the company’s audited financial statements for FY26 and reappointed two non-executive directors at its 33rd Annual General Meeting (AGM) held on August 11, 2026. The meeting, chaired by Chairman and Managing Director Ashish Dandekar, was conducted via Video Conferencing (VC) / Other Audio Visual Means (OAVM) in compliance with Ministry of Corporate Affairs and Securities and Exchange Board of India (SEBI) circulars. All four resolutions passed with requisite majority, reflecting strong stakeholder alignment.

The AGM transacted ordinary business including the adoption of standalone and consolidated financial statements for FY26, alongside the re-appointment of Harsha Raghavan and Jens Van Nieuwenborgh as Non-Executive Non-Independent Directors, who retired by rotation. Under special business, shareholders ratified the remuneration of the Cost Auditor for the financial year ending March 31, 2027. The proceedings were scrutinized by Jayant Ranade of JHR & Associates, appointed as Scrutinizer pursuant to Section 108 of the Companies Act, 2013 and Regulation 44 of the SEBI Listing Regulations.

Voting participation was robust, with 56.83% of outstanding shares polled across all resolutions. Promoter and Promoter Group shareholders, holding 92,264,053 shares, voted in favor of all resolutions with 100% support. Public Institutional shareholders also demonstrated high engagement, polling over 84% of their holdings. Remote e-voting was open from August 8 to August 10, 2026, while additional voting occurred during the live meeting session.

Voting Results Summary

The Statutory Auditor’s report contained no qualifications or adverse remarks, as noted by the Chairman during the proceedings. The Scrutinizer’s consolidated report confirmed that no invalid votes were identified during the scrutiny process. A limited number of abstentions were recorded for specific resolutions but were classified separately as votes not cast.

What the Numbers Show

The near-unanimous approval of all resolutions underscores stable shareholder confidence in Camlin Fine Sciences’ governance structure. The promoter group’s complete alignment with all proposals, combined with high institutional participation, suggests minimal dissent regarding the company’s strategic direction and financial reporting for FY26. The negligible percentage of votes against any resolution indicates broad consensus among equity holders.

Camlin Fine Sciences Limited has scheduled a Q1 FY27 earnings conference call on Tuesday, August 11, 2026 at 5:00 PM IST, to discuss the company's unaudited financial results for the quarter ended June 30, 2026. The intimation was filed pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has clarified that discussions during the call will be based solely on publicly available information, and no unpublished price-sensitive information (UPSI) is intended to be discussed.

Call Details and Access Information

Investors and analysts are requested to pre-register for the call via the link provided by the company. The following dial-in access numbers have been made available for participation across multiple geographies:

Senior Management Participants

The earnings call will feature the following senior management representatives from Camlin Fine Sciences:

• Mr. Ashish Dandekar – Chairman & Managing Director
• Mr. Nirmal Momaya – Managing Director
• Mr. Santosh Parab – Chief Financial Officer

RSVP and Investor Relations Contact

The call is being coordinated by Strategic Growth Advisors Pvt. Ltd. Interested participants may reach out to the investor relations team for further assistance:

The company has noted that the scheduled date of the call is subject to change due to exigencies on the part of analysts, investors, or the company. The filing was signed by Rahul Sawale, Company Secretary & VP Legal, on August 4, 2026.